Kongres EAACI 2024: Inovasi dan Kemajuan dalam Rawatan Alahan
30 avr. 2024 02h58 HE
|
European Academy of Allergy and Clinical Immunology
Lebih 150 sesi saintifik akan dibentangkan semasa kongres itu, yang antara lainnya memfokuskan kepada kemajuan dalam sains alam sekitar, alahan makanan, inovasi dalam imunoterapi dan alahan...
2024년도 EAACI 학술대회: 알레르기 치료의 혁신과 발전
30 avr. 2024 02h58 HE
|
European Academy of Allergy and Clinical Immunology
학술대회 일환으로 환경 과학, 식품 알레르기, 면역 치료 혁신, 소아 알레르기 등의 주제에 초점 맞춘 150개 이상의 과학 세션 열릴 예정최대 규모의 알레르기 및 면역학 학술대회에서 다뤄질 정밀 의학, AI, 면역 치료, 면역 조절제5월 31일부터 6월 3일까지 스페인 발렌시아에서 개최 스페인 발렌시아, April 30, 2024 (GLOBE...
欧州アレルギー・臨床免疫学会2024 (EAACI Congress 2024)：アレルギー治療の革新と進歩
30 avr. 2024 02h58 HE
|
European Academy of Allergy and Clinical Immunology
学会中は、環境科学の進歩、食物アレルギー、免疫療法の革新、小児アレルギーなどに焦点を当てた、150を超える科学セッションが開催される。精密医療、AI、免疫療法、免疫調節剤が、最大規模のアレルギーおよび免疫学学会に集結。同学会は、5月31日から6月3日までスペインのバレンシアで開催される。 スペイン、バレンシア発, April 30, 2024 (GLOBE NEWSWIRE) --...
Kongres EAACI 2024: Inovasi dan Kemajuan dalam Pengobatan Alergi
30 avr. 2024 02h58 HE
|
European Academy of Allergy and Clinical Immunology
Lebih dari 150 sesi ilmiah akan dipresentasikan selama pelaksanaan kongres, dengan fokus di berbagai bidang yang di antaranya mencakup kemajuan dalam sains lingkungan, alergi makanan, inovasi...
Congrès EAACI 2024 : innovations et progrès dans le traitement des allergies
30 avr. 2024 02h58 HE
|
European Academy of Allergy and Clinical Immunology
Lors de ce congrès, plus de 150 sessions scientifiques seront présentées. Les sujets abordés se concentreront sur les progrès de la science environnementale, les allergies alimentaires, les...
2024 年欧洲过敏与临床免疫学会大会：过敏治疗的创新和进步
30 avr. 2024 02h58 HE
|
European Academy of Allergy and Clinical Immunology
大会期间将举行 150 多场科学会议，重点探讨环境科学、食物过敏、免疫疗法创新和儿科过敏等方面的进展。作为规模最大的过敏和免疫学盛会，本次大会将汇聚精准医学、人工智能、免疫疗法和免疫调节剂等前沿领域。大会将于 5 月 31 日至 6 月 3 日在西班牙巴伦西亚举行。 巴伦西亚，西班牙, April 30, 2024 (GLOBE NEWSWIRE) -- 由来自 125 个国家的...
Medigene AG reports Financial Results and Business Update for Q1 2024
26 avr. 2024 03h00 HE
|
Medigene AG
Planegg/Martinsried, April 26, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene presents streamlined 6-day, high stemness TCR-T therapy production process
25 avr. 2024 09h00 HE
|
Medigene AG
Planegg/Martinsried, April 25, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases
24 avr. 2024 07h00 HE
|
Biolojic Design
Nektar Therapeutics Has Exercised Its License Option to Develop Biolojic Design's AI-Designed Antibody Targeting TNFR2 in Immunology
Medigene to Present at Upcoming Scientific Conferences
17 avr. 2024 06h00 HE
|
Medigene AG
Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, has been...